Retour sur lavenir.net
   AZELIS GROUP 11.990 € (+1,18 %)     KBC ANCORA 92.100 € (-0,97 %)     AB INBEV 72.980 € (-1,38 %)     GBL 77.550 € (-0,70 %)     UMICORE 17.760 € (-1,77 %)     ARGENX SE 788.800 € (+0,61 %)     ONWARD MEDICAL 1.890 € (-11,48 %)     NYXOAH 0.780 € (-2,50 %)     BREDERODE 100.000 € (-1,38 %)     SOLVAY 23.460 € (-1,92 %)     D'IETEREN GROUP 177.000 € (-0,34 %)     EVS 18.000 € (+2,74 %)     WDP 19.130 € (-1,39 %)     ASCENCIO 53.500 € (+1,33 %)     RECTICEL 12.180 € (-1,62 %)     BANQUP GROUP 0.800 € (-6,32 %)     CFE 10.850 € (+2,36 %)     OPTION 2.720 € (-5,56 %)     CARE PROPERTY INV. 12.400 € (-0,32 %)     COLRUYT 35.240 € (+0,69 %)     CIE BOIS SAUVAGE 271.000 € (0,00 %)     IBA 16.100 € (-0,25 %)     VAN DE VELDE 29.300 € (0,00 %)     AGFA-GEVAERT 0.389 € (+0,65 %)     SYENSQO 76.800 € (0,00 %)     XIOR 25.000 € (-0,20 %)     AEDIFICA 64.450 € (+0,08 %)     AGEAS 75.800 € (-0,07 %)     BPOST 1.106 € (-2,12 %)     VGP 63.300 € (+1,93 %)     BEKAERT 41.000 € (+0,49 %)     TINC 10.340 € (-0,19 %)     GIMV 49.250 € (-1,50 %)     DECEUNINCK 2.405 € (+0,21 %)     CMB.TECH 15.400 € (-1,79 %)     PROXIMUS 6.060 € (-0,41 %)     WERELDHAVE BELGIUM 50.000 € (-1,19 %)     KINEPOLIS GROUP 48.700 € (-0,41 %)     UCB 276.500 € (-0,58 %)     NEXTENSA 45.550 € (-0,98 %)     DEME GROUP 169.200 € (0,00 %)     ACKERMANS V.HAAREN 266.000 € (-1,34 %)     IMMOBEL 17.650 € (-0,84 %)     LOTUS BAKERIES 13 740.000 € (0,00 %)     ECONOCOM GROUP 1.500 € (+1,35 %)     RETAIL ESTATES 62.300 € (-0,32 %)     SIPEF 110.200 € (-0,36 %)     SOFINA 276.000 € (-3,16 %)     ENERGYVISION 17.840 € (+1,59 %)     ONTEX GROUP 1.558 € (+9,72 %)     ORANGE BELGIUM 22.200 € (-0,45 %)     KBC 113.600 € (-1,09 %)     BIOTALYS 1.920 € (+19,25 %)     JENSEN-GROUP 73.200 € (+0,27 %)     SHURGARD 24.750 € (-2,37 %)     TESSENDERLO 17.380 € (-0,69 %)     TUBIZE-FIN 227.400 € (-0,09 %)     VASTNED 27.200 € (-0,18 %)     INCLUSIO SA/NV 15.150 € (+0,33 %)     HOME INVEST BE. 17.600 € (-0,45 %)  
   SANOFI 80.980 € (+0,43 %)     ASM INTERNATIONAL 720.000 € (+0,25 %)     THEON INTERNAT 29.660 € (0,00 %)     GTT 187.300 € (+1,46 %)     NANOBIOTIX 25.540 € (+0,87 %)     TOTALENERGIES 82.710 € (-1,08 %)     INVENTIVA 3.550 € (+10,08 %)     KERING 180.240 € (+0,32 %)     CSG 14.082 € (-1,14 %)     PHILIPS KON 25.700 € (+4,81 %)     IT LINK 13.700 € (+5,79 %)     BAM GROEP KON 12.710 € (+0,16 %)     L'OREAL 432.700 € (-0,87 %)     ALSTOM 11.125 € (-4,79 %)     CEGEDIM 9.630 € (-0,41 %)     AIRBUS 193.320 € (-1,41 %)     LVMH 401.500 € (+1,99 %)     HEINEKEN HOLDING 77.150 € (-0,58 %)     SCHNEIDER ELECTRIC 239.750 € (-0,29 %)     MAGNUM 17.434 € (-3,27 %)     ADYEN 827.800 € (-2,75 %)     STELLANTIS NV 4.084 € (-3,68 %)     DANONE 66.020 € (-0,06 %)     PROSUS 35.270 € (+0,23 %)     RELX 35.400 € (-1,45 %)     SHELL PLC 46.515 € (-1,23 %)     PHARMING GROUP 1.134 € (+0,98 %)     ORANGE 14.700 € (+1,48 %)     ASML HOLDING 1 385.000 € (-1,63 %)     AXA 43.050 € (+0,19 %)     HEINEKEN 80.840 € (-0,79 %)     STMICROELECTRONICS 43.100 € (-0,27 %)     BUREAU VERITAS 29.150 € (-0,17 %)     EUROCOMMERCIAL 25.000 € (+1,01 %)     HAFFNER ENERGY 0.640 € (+5,96 %)     CRCAM BRIE PIC2CCI 28.140 € (+2,18 %)     BNP PARIBAS ACT.A 87.610 € (+0,65 %)     MAROC TELECOM 8.160 € (0,00 %)     ABN AMRO BANK N.V. 39.770 € (-0,57 %)     AMUNDI 92.600 € (-0,43 %)     AKZO NOBEL 61.160 € (-1,26 %)     TELEPERFORMANCE 80.980 € (-1,34 %)     SWORD GROUP 34.450 € (+0,58 %)     BE SEMICONDUCTOR 156.100 € (+1,69 %)     FLOW TRADERS 22.580 € (-0,53 %)     ICAPE HOLDING 9.800 € (0,00 %)     CTP 12.820 € (+0,79 %)     ADP 114.300 € (-0,44 %)     MEDINCELL 27.840 € (+3,42 %)     VALEO 10.920 € (-3,32 %)     ID LOGISTICS GROUP 372.500 € (+0,40 %)     CREDIT AGRICOLE 15.020 € (+0,54 %)     DASSAULT SYSTEMES 24.980 € (-2,50 %)     PUBLICIS GROUPE SA 101.150 € (+0,15 %)     ING GROEP N.V. 27.715 € (-1,49 %)     CROSSJECT 1.198 € (-4,16 %)     SAFRAN 285.000 € (-1,11 %)     PERNOD RICARD 68.260 € (-0,96 %)     GECINA 64.550 € (-1,22 %)     VOPAK 53.150 € (-1,30 %)  
ABIVAX
ABVX - FR0012333284 - Euronext Paris
79,250 €  17:35
+4,21 %
02/11/2026 22:05

Abivax to Participate in Upcoming Fall Investor Conferences

EQS-News: ABIVAX / Key word(s): Conference
Abivax to Participate in Upcoming Fall Investor Conferences

02.11.2026 / 22:05 CET/CEST
The issuer is solely responsible for the content of this announcement.

Abivax to Participate in Upcoming Fall Investor Conferences

PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences:

Guggenheim Healthcare Innovation Conference
Boston, Massachusetts
November 9-11, 2026
Fireside Chat: Tuesday, November 10th, 10:30-10:55am ET

LifeSci Capital X Sofinnova Growth & Innovation Summit
London, United Kingdom
November 16, 2026

30th German Equity Forum (Deutsches Eigenkapitalforum)
Frankfurt, Germany
November 23-25, 2026
Corporate Presentation: Monday, November 23rd, 11:40am-12:10pm CET

Evercore ISI 9th Annual Healthcare Conference
Miami, Florida
November 30 – December 2, 2026
Fireside Chat: Wednesday, December 2nd, 7:55-8:15am ET

Piper Sandler 38th Annual Healthcare Conference
New York, New York
December 1-3, 2026
Fireside Chat: Thursday, December 3rd, 8:00-8:25am ET

Webcast links for select presentations will be available in the Investors section of Abivax’s website at www.ir.abivax.com. A replay of the available webcasts will also be available on the Company’s website for a limited time following the conference.


About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.


Contact:

Abivax SA
Patrick Malloy
SVP, Investor Relations
patrick.malloy@abivax.com
+1 847 987 4878

Media Contact:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com


02.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

2426792  02.11.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière